➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Harvard Business School
Express Scripts
Merck
Mallinckrodt

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

CEFOXITIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Cefoxitin, and when can generic versions of Cefoxitin launch?

Cefoxitin is a drug marketed by Acs Dobfar, Acs Dobfar Spa, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira Inc, West-ward Pharms Int, B Braun, and Samson Medcl. and is included in fourteen NDAs.

The generic ingredient in CEFOXITIN is cefoxitin sodium. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the cefoxitin sodium profile page.

Drug patent expirations by year for CEFOXITIN
Drug Prices for CEFOXITIN

See drug prices for CEFOXITIN

Recent Clinical Trials for CEFOXITIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cystic Fibrosis FoundationPhase 2/Phase 3
South Australian Health and Medical Research InstitutePhase 2/Phase 3
Hôpital CochinPhase 2/Phase 3

See all CEFOXITIN clinical trials

Pharmacology for CEFOXITIN

US Patents and Regulatory Information for CEFOXITIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acs Dobfar CEFOXITIN cefoxitin sodium INJECTABLE;INJECTION 065414-001 Jun 12, 2009 AP RX No Yes   Start Trial   Start Trial   Start Trial
West-ward Pharms Int CEFOXITIN cefoxitin sodium INJECTABLE;INJECTION 065050-001 Sep 11, 2000 AP RX No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa CEFOXITIN cefoxitin sodium INJECTABLE;INJECTION 065012-001 Jul 3, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Acs Dobfar Spa CEFOXITIN cefoxitin sodium INJECTABLE;INJECTION 065467-001 Aug 31, 2011 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Harvard Business School
Dow
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.